Antithrombotic agents, blood substitutes and perfusion solutions, and antihemorrhagics

Finnish Institute for Health and Welfare, later referred to as THL or Customer, requested tenders for "Antithrombotic agents, blood substitutes and perfusion solutions, and antihemorrhagics" to the rescEU Medical -project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in five (5) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots. LOT 1: Enoxaparin sodium 100 mg/ml (1 ml sub cutan, vial/ampoule/prefilled syringe, ATC B01AB05) LOT 2: 5 % glucose electrolyte solution (1000 ml, i.v., infusion bag, 5 % solution, ATC B05BB02) LOT 3: Calcium gluconate 100 mg/ml (10 ml i.v., vial/ampoule, ATC B05BB01) LOT 4: Freeze-dried plasma, powder and solvent for infusion (200 ml, bottle, ATC B05AA) LOT 5: Tranexamic acid 100 mg/ml (10 ml, i.v., vial/ampoule, ATC B02AA02) The minimum requirements for the products is described in Annex 1.1. The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the Contract has been signed by contracting parties and expires when all contractual duties of the Contract have been performed. Quantity for the products is described in Annex 7 (restricted to security classification level IV, TL IV). In addition to the quantity indicated in the Annex 7, the Customer is entitled to purchase 100 % extra to the quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option. Please note that all times given in the Call for tenders refer to local time in Finland. Call for tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Description of the rotation Annex 2.1 Quality scoring table Annex 3 Contract Annex 4 Security annex Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Confidentiality commitment Annex 7 Quantity of the Articles (restricted, TL IV) Please note that the numbering of the annexes differs between the Contract and the Call for tenders. The numbering of the Annexes to the Contract is based on the order of precedence applied in the Contract., LOT 1: Enoxaparin sodium 100 mg/ml (1 ml sub cutan, 100 mg per vial/ampoule/prefilled syringe, ATC B01AB05) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Enoxaparin sodium 100 mg/ml (1 ml sub cutan, 100 mg per vial/ampoule/prefilled syringe, ATC B01AB05) - Parenteral products (subcutaneous administration) - Active pharmaceutical ingredient: Enoxaparin sodium - Strength: 100 mg/ml - Pharmaceutical form: 1 ml sub cutan, 100 mg per vial/ampoule/prefilled syringe The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 2: 5 % glucose electrolyte solution (1000 ml, i.v., infusion bag, 5 % solution, ATC B05BB02) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: 5 % glucose electrolyte solution (1000 ml, i.v., infusion bag, 5 % solution, ATC B05BB02) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Glucose electrolyte solution - Strength: 5% - Pharmaceutical form: 1000 ml infusion bag The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) or two (2) Articles. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 3: Calcium gluconate 100 mg/ml (10 ml i.v., 1000 mg per vial/ampoule, ATC B05BB01) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Calcium gluconate 100 mg/ml (10 ml i.v., 1000 mg per vial/ampoule, ATC B05BB01) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Calcium gluconate - Strength: 100 mg/ml - Pharmaceutical form: 10 ml i.v., 1000 mg per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 4: Freeze-dried plasma, powder and solvent for infusion (200 ml, bottle, ATC B05AA) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Freeze-dried plasma, powder and solvent for infusion (200 ml, bottle, ATC B05AA) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Freeze-dried plasma - Pharmaceutical form: 200 ml, bottle The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition., LOT 5: Tranexamic acid 100 mg/ml (10 ml, i.v., 1000 mg per vial/ampoule, ATC B02AA02) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Tranexamic acid 100 mg/ml (10 ml, i.v., 1000 mg per vial/ampoule, ATC B02AA02) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Tranexamic acid - Strength: 100 mg/ml - Pharmaceutical form: 10 ml, i.v., 1000 mg per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.,